|Day Low/High||8.17 / 8.90|
|52 Wk Low/High||2.52 / 9.78|
Here's what you need to know now for Monday, Jan. 22.
Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.
Investors eyeing a purchase of Fate Therapeutics Inc shares, but cautious about paying the going market price of $6.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $5 strike, which has a bid at the time of this writing of 60 cents.
More Immunotherapy Buyouts Likely After Kite Sale
Patent Broadly Protects the Use of Prostaglandins for Enhancing Gene Transfer in Blood Stem Cells
Fate's first subject has been treated with FATE-NK100 for AML and two additional clinical trials of FATE-NK100 for the treatment of multiple advanced solid tumor types will soon open.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.